Nucleic Acid Therapeutics

Papers
(The H4-Index of Nucleic Acid Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations129
Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides103
Combined 20-Hydroxyecdysone and Antisense-Mediated Exon Skipping Improve Functional Outcomes in a Mouse Model of Duchenne Muscular Dystrophy87
SIDT2 Inhibits Phosphorothioate Antisense Oligonucleotide Activity by Regulating Cellular Localization of Lysosomes77
Quantification of mRNA Decay Rates in HeLa and SH-SY5Y Cell Lines Reveals Novel Properties of Membrane Protein Coding Transcripts48
Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates47
Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment42
Correction to: Understanding and Rescuing the Splicing Defect Caused by the Frequent ABCA4 Variant c.4253 + 43G>A Underlyin38
Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Du30
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids24
Reversible Aptamer Staining, Sorting, and Cleaning of Cells (Clean FACS) with Antidote Oligonucleotide or Nuclease Yields Fully Responsive Cells20
Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection20
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products19
Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics19
Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition19
Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs18
Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2′- O -Methyl Modified Single-Stranded Oligonucleotides17
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy17
0.14347386360168